Project Details


In the proposed research I aim to inhibit 'trained immunity', a recently discovered pro-inflammatory state of the innate immune system. This system plays a major role in both atherosclerosis and ischemic heart disease. Utilizing high density lipoprotein (HDL) nanobiologic platform technology, we pursue to target innate immune cells and inhibit the epigenetic modifications defining trained immunity. In this study I will exploit a variety of experimental procedures and techniques. Bone marrow derived macrophages will be used to study the in vitro effects of a library of HDL nanobiologics. Most promising formulations will be extensively evaluated in vivo. Apolipoprotein E deficient (Apoe-/-) mice will be used as a model for atherosclerosis. In these mice, atherosclerotic plaque inflammation will be assessed by flow cytometry, histology and in vivo imaging. To study the therapeutic efficacy of the nanobiologics on ischemic heart disease, mice will be subjected to coronary artery ligation. Cardiac function and infarct size will be evaluated by in vivo imaging. Finally, nanobiologic's efficacy will also be determined by mapping systemic inflammation and the epigenetic signature in both disease models. (AHA Program: Predoctoral Fellowship)

Effective start/end date1/01/1931/12/20


  • American Heart Association: $54,000.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.